Catégories
Documents Tout le CNR-MyRMA

Publications – Tuberculose

Seules les publications les plus récentes sont présentées – Pour voir plus de publications aller à la page de recherche : toutes les publications
Only the most recent publications are displayed – to see more, go to the search page : all publications

Günther, G., Guglielmetti, L., Leu, C., van Leth, F. and Lange, C. (2023). Relative cost of multidrug-resistant TB medicines in Europe. The International Journal of Tuberculosis and Lung Disease 27, 341–344, http://doi.org/10.5588/ijtld.23.0026.
Campbell, J. R., Chan, E. D., Anderson, L. F., Bonnet, M., Brode, S. K., Cegielski, J. P., Guglielmetti, L., Singla, R., Fox, G. J., Skrahina, A., Rodrigues, D., Kuksa, L., Viiklepp, P. and Menzies, D. (2023). Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes. The International Journal of Tuberculosis and Lung Disease 27, 338–340, http://doi.org/10.5588/ijtld.22.0678.
Guthmann, J.-P., Fraisse, P., Bonnet, I. and Robert, J. (2023). Active tuberculosis screening among the displaced population fleeing Ukraine, France, February to October 2022. Eurosurveillance 28, http://doi.org/10.2807/1560-7917.ES.2023.28.12.2300155.
Aubry, A. and Veziris, N. (2023). La tuberculose, l’une des plus anciennes maladies infectieuses : quelles avancées récentes majeures ? Med Sci (Paris) 39, 203–204, http://doi.org/10.1051/medsci/2023054.
Masini, T., Furin, J., Udwadia, Z. and Guglielmetti, L. (2023). Optimal management of drug-resistant tuberculosis: Can India lead the way? Indian Journal of Medical Research 157, 220, http://doi.org/10.4103/ijmr.ijmr_300_23.
Domínguez, José, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna M, Maurer, F. P., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles R, Lange, C., Domínguez, Jose, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna Maria, Maurer, F., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles Robert and Lange, C. (2023). Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(22)00875-1.
Barbier, E., Fouchet, T., Hartmann, A., Cambau, E., Mougari, F., Dubois, C., Lubetzki, M. and Rochelet, M. (2023). Rapid electrochemical detection of Mycobacterium tuberculosis in sputum by measuring Ag85 activity with disposable carbon sensors. Talanta 253, 123927, http://doi.org/10.1016/j.talanta.2022.123927.
Khan, U. and Guglielmetti, L. (2023). Tailored TPT for drug-resistant TB - promoting equity and access to optimal care. Int J Tuberc Lung Dis 27, 89b–890, http://doi.org/10.5588/ijtld.22.0538.
Günther, G., Guglielmetti, L., Leu, C., Lange, C., van Leth, F., Hasan Hafizi, Khachatryan, N., Aroyan, H., Kabasakalyan, E., Knappik, M., Skrahina, A., Klimuk, D., Nikolenka, A., Muylle, I., Milanov, V., Velkovska, D., Tarinska, N., Bachiyska, E., Jankovic, M., Pieridou, D., Adamide, T., Nicolaou, N., Vasakova, M., Sukholytka, M., Kopeckà, E., Folkvardsen, D. B., Svensson, E., Danilovits, M., Kummik, T., Vasankari, T., Fréchet-Jachym, M., Nahmiash, A., Togonidze, T., Avaliani, Z., Kinkladze, I., Aspindzelashvili, R., Bichashvili, T., Losaberidze, G., Merabishvili, T., Kalsdorf, B., Manika, K., Tsiakitzis, K., Bakos, A., Ægisdóttir, T. R., Michelsen, G. S., Karlsdóttir, K., McLaughlin, A.-M., Fitzgibbon, M., Chemtob, D., Codecasa, L. R., Ferrarese, M., Torri, S., Gjocaj, M., Kuksa, L., Davidaviciene, E., Wirtz, G., Perrin, M., Asciak, A. P., Chesov, D., de Lange, W., Akkerman, O., Poposka, B. I., Mack, U., Jensenius, M., Kvalvik, L., Mengshoel, A. T., Kruczak, K., Duarte, R., Ribeiro, N., Ibraim, E., Kaluzhenina, A., Barkanova, O., Pesut, D., Solovic, I., Svetina, P., Souza-Galvão, M.-L. de, Millet, J.-P., Casas, X., Vives, M., Bruchfeld, J., Dalemo, P., Jonsson, J., Aeschbacher, K., Keller, P., Özkara, S., Tiberi, S., Chen, C., Terleeva, Y. and Dudnyk, A. (2023). Availability and costs of medicines for the treatment of tuberculosis in Europe. Clinical Microbiology and Infection 29, 77–84, http://doi.org/10.1016/j.cmi.2022.07.026.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D. and Guglielmetti, L. (2021). TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 22, 1–3, http://doi.org/10.1186/s13063-021-05331-4.
Bonnet, I., Enouf, V., Morel, F., Ok, V., Jaffré, J., Jarlier, V., Aubry, A., Robert, J. and Sougakoff, W. (2021). A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 11, 707244, http://doi.org/10.3389/fcimb.2021.707244.
Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. D. S., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F. and Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials 22, 651, http://doi.org/10.1186/s13063-021-05491-3.
Roelens, M., Battista Migliori, G., Rozanova, L., Estill, J., Campbell, J. R., Cegielski, J. P., Tiberi, S., Palmero, D., Fox, G. J., Guglielmetti, L., Sotgiu, G., Brust, J. C. M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O. and Raviglione, M. (2021). Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 204, 713–722, http://doi.org/10.1164/rccm.202009-3527OC.
Veziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J. and Aubry, A. (2021). Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal 58, http://doi.org/10.1183/13993003.00641-2021.
Starshinova, A., Guglielmetti, L., Rzhepishevska, O., Ekaterincheva, O., Zinchenko, Yu. and Kudlay, D. (2021). Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). J Clin Tuberc Other Mycobact Dis 24, 100259, http://doi.org/10.1016/j.jctube.2021.100259.
Ok, V., Aubry, A., Morel, F., Bonnet, I., Robert, J. and Sougakoff, W. (2021). Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics 10, 797, http://doi.org/10.3390/antibiotics10070797.
Hewison, C. and Guglielmetti, L. (2021). Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. Lancet Infect Dis 21, 894–895, http://doi.org/10.1016/S1473-3099(20)30836-7.
Guglielmetti, L. and Varaine, F. (2021). The coming-of-age of bedaquiline: a tale with an open ending. European Respiratory Journal 57, http://doi.org/10.1183/13993003.00066-2021.
World Health Organisation (2021). Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), WHO, Geneva, URL: https://www.who.int/publications/i/item/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine) [Accessed March 2022].
Maitre, T., Guglielmetti, L. and Veziris, N. (2021). Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal 57, http://doi.org/10.1183/13993003.04315-2020.
Mohamed, S., Köser, C. U., Salfinger, M., Sougakoff, W. and Heysell, S. K. (2021). Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics? European Respiratory Journal 57, http://doi.org/10.1183/13993003.04077-2020.
Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2021). Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection 27, 288.e1-288.e4, http://doi.org/10.1016/j.cmi.2020.10.019.
Molina‐Moya, B., Guglielmetti, L., Bothamley, G., van Leth, F., Lange, C., Dominguez, J. and TBnet Study Group (2021). Use and impact of molecular methods for detecting drug‐resistant TB. The International Journal of Tuberculosis and Lung Disease 25, 157–159, http://doi.org/10.5588/ijtld.20.0527.
Calin, R., Belkacem, A., Caraux-Paz, P., Wagner, M., Guillot, H., Veziris, N., Jaureguiberry, S., Caumes, E., Patey, O. and Pourcher, V. (2021). Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region. The American Journal of Tropical Medicine and Hygiene 104, 223–228, http://doi.org/10.4269/ajtmh.20-0023.
Tagliani, E., Anthony, R., Kohl, T. A., de Neeling, A., Nikolayevskyy, V., Ködmön, C., Maurer, F. P., Niemann, S., van Soolingen, D., van der Werf, M. J. and Cirillo, D. M. (2021). Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017–2019: an ECDC pilot study. Eur Respir J 57, 2002272, http://doi.org/10.1183/13993003.02272-2020.
Maitre, T., Ok, V., Morel, F., Bonnet, I., Sougakoff, W., Robert, J., Trosini, V., Caumes, E., Aubry, A. and Veziris, N. (2021). Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research 79, 100825, http://doi.org/10.1016/j.resmer.2021.100825.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, Typhaine, Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N., Robert, J., Bouchaud, O., Billard-Pomares, T., Carbonnelle, E., Mechaï, F., Nunes, H., Pellan, M., Morin, A.-S., Dumesnil, C., Dumoulin, J., Roux, A.-L., Jachym, M., le Du, D., Marigot-Outtandy, D., Abgrall, S., Chambrin, V., Guillet, C., Fantin, B., Galy, A., Decousser, J.-W., Lelièvre, J. D., Gallien, S., Nebbad-Lechani, B., Deconinck, L., Bulifon, S., Fortineau, N., Wyplosz, B., Cohen, F., Lemaitre, N., Crestani, B., Grall, N., Pierre-Audigier, C., Rioux, C., Yazdanpanah, Y., Le Jeunne, C., Morand, P., Roche, N., Pavie, J., Loulergue, P., Delcey, V., Lecorché, E., Munier, A.-L., Mougari, F., Sellier, P., Bille, E., Ferroni, A., Guéry, R., Hummel, A., Lourenco, J., Aubry, A., Bonnet, I., Caumes, E., Londner, C., Morel, F., Lacombe, K., Lalande, V., Meynard, J.-L., Veziris, N., De Castro, N., Denis, B., Lafaurie, M., Molina, J.-M., Canestri, A., Lassel, L., Pialoux, G., Verdet, C., Nardi, A.-L., Gominet, M. and Catherinot, E. (2021). Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases 107, 86–91, http://doi.org/10.1016/j.ijid.2021.03.093.
Opota, O., Mazza-Stalder, J., Viveiros, M., Cambau, E., Santin, M. and Goletti, D. (2021). Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. Frontiers in Public Health 9, URL: https://www.frontiersin.org/article/10.3389/fpubh.2021.666187 [Accessed March 2022].
Gies, V., Dieudonné, Y., Morel, F., Sougakoff, W., Carapito, R., Martin, A., Weingertner, N., Jacquel, L., Hubele, F., Kuhnert, C., Jung, S., Schramm, F., Boyer, P., Hansmann, Y., Danion, F., Korganow, A.-S. and Guffroy, A. (2021). Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy. Front Immunol 12, 696268, http://doi.org/10.3389/fimmu.2021.696268.
Rousset, L., Sokal, A., Vignon-Pennamen, M.-D., Pagis, V., Rybojad, M., Lecorche, E., Mougari, F., Bagot, M., Bouaziz, J.-D. and Jachiet, M. (2020). Association d’une lèpre borderline tuberculoïde et d’une tuberculose : un cas et revue de la littérature. Annales de Dermatologie et de Vénéréologie 147, 886–891, http://doi.org/10.1016/j.annder.2020.09.571.
Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2020). Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates – the EUCAST broth microdilution reference method for MIC determination. Clinical Microbiology and Infection 26, 1488–1492, http://doi.org/10.1016/j.cmi.2020.07.036.
Cox, V., McKenna, L., Acquah, R., Reuter, A., Wasserman, S., Vambe, D., Ustero, P., Udwadia, Z., Triviño-Duran, L., Tommasi, M., Skrahina, A., Seddon, J. A., Rodolfo, R., Rich, M., Padanilam, X., Oyewusi, L., Ohler, L., Lungu, P., Loveday, M., Khan, U., Khan, P., Hughes, J., Hewison, C., Guglielmetti, L. and Furin, J. (2020). Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB. The International Journal of Tuberculosis and Lung Disease 24, 1134–1144, http://doi.org/10.5588/ijtld.20.0330.
Schön, T., Köser, C. U., Werngren, J., Viveiros, M., Georghiou, S., Kahlmeter, G., Giske, C., Maurer, F., Lina, G., Turnidge, J., Ingen, J. van, Jankovic, M., Goletti, D., Cirillo, D. M., Santin, M. and Cambau, E. (2020). What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex? Clinical Microbiology and Infection 26, 1453–1455, http://doi.org/10.1016/j.cmi.2020.07.037.

Catégories
Documents Tout le CNR-MyRMA

Publications du CNR en 2022

Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Chaptal, M., Andrejak, C., Bonifay, T., Beillard, E., Guillot, G., Guyomard-Rabenirina, S., Demar, M., Trombert-Paolantoni, S., Jacomo, V., Mosnier, E., Veziris, N., Djossou, F., Epelboin, L. and Group, F. G. P. working (2022). Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008–2018. PLOS Neglected Tropical Diseases 16, e0010693, http://doi.org/10.1371/journal.pntd.0010693.
Chiron, R., Hoefsloot, W., Van Ingen, J., Marchandin, H., Kremer, L., Morisse-Pradier, H., Charriot, J., Mallet, J.-P., Herrmann, J.-L., Caimmi, D., Moreau, J., Dumont, Y., Godreuil, S., Bergeron, A., Drevait, M., Bouzat-Rossigneux, E., Terrail, N., Andrejak, C., Veziris, N., Grenet, D., Coudrat, A. and Catherinot, E. (2022). Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience. Open Forum Infect Dis 9, ofac465, http://doi.org/10.1093/ofid/ofac465.
Daniau, C., Lecorche, E., Mougari, F., Benmansour, H., Bernet, C., Blanchard, H., Robert, J., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020. Emerg Infect Dis 28, 518–526, http://doi.org/10.3201/eid2803.211791.
Daniau, C., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerg Infect Dis 28, 1303–1304, http://doi.org/10.3201/eid2806.220686.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Kilinç, G., Walburg, K. V., Franken, K. L. M. C., Valkenburg, M. L., Aubry, A., Haks, M. C., Saris, A. and Ottenhoff, T. H. M. (2022). Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Front Cell Infect Microbiol 12, 872361, http://doi.org/10.3389/fcimb.2022.872361.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Lange, C., Böttger, E. C., Cambau, E., Griffith, D. E., Guglielmetti, L., van Ingen, J., Knight, S. L., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Winthrop, K., Daley, C. L., Lange, C., Andrejak, C., Böttger, E., Cambau, E., Griffith, D., Guglielmetti, L., van Ingen, J., Knight, S., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Wallace, R. J., Winthrop, K. and Daley, C. (2022). Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(21)00586-7.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Vongthilath-Moeung, R., Plojoux, J., Poncet, A., Renzi, G., Veziris, N., Schrenzel, J. and Janssens, J.-P. (2022). Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015–2020). RES 101, 367–375, http://doi.org/10.1159/000520033.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.

Publications du CNR en 2014

Atallah, D., El Kassis, N., Araj, G., Nasr, M., Nasnas, R., Veziris, N. and Sarkis, D. (2014). Mycobacterial infection of breast prosthesis – a conservative treatment: a case report. BMC Infectious Diseases 14, 238, http://doi.org/10.1186/1471-2334-14-238.
Aubry, A., Sougakoff, W., Bodzongo, P., Delcroix, G., Armand, S., Millot, G., Jarlier, V., Courcol, R. and Lemaître, N. (2014). First Evaluation of Drug-Resistant Mycobacterium tuberculosis Clinical Isolates from Congo Revealed Misdetection of Fluoroquinolone Resistance by Line Probe Assay Due to a Double Substitution T80A-A90G in GyrA. PLoS ONE 9, e95083, http://doi.org/10.1371/journal.pone.0095083.
Bastos, M. L., Hussain, H., Weyer, K., Garcia-Garcia, Lourdes, Leimane, Vaira, Leung, Chi Chiu, Narita, Masahiro, Penã, J. M., Ponce-de-Leon, Alfredo, Seung, Kwonjune J., Shean, Karen, Sifuentes-Osornio, José, Walt, M. V. der, Werf, T. S. V. der, Yew, Wing Wai, Menzies, Dick, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Becerra, M., Benedetti, A., Burgos, M., Centis, R., Chan, E. D., Chiang, C. Y., Cobelens, F., Cox, H., D’Ambrosio, L., Lange, W. C. M. de, DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R. M., Hollm-Delgado, M. G., Holtz, T. H., Hopewell, P., Iseman, M., Jarlsberg, L. G., Keshavjee, S., Kim, H. R., Koh, W. J., Lancaster, J., Lange, C., Leimane, V., Leung, C. C., Li, J., Menzies, D., Migliori, G. B., Mitnick, C. M., Narita, M., Nathanson, E., Odendaal, R., O’Riordan, P., Pai, M., Palmero, D., Park, S. K., Pasvol, G., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M. I. D., Quy, H. T., Riekstina, V., Robert, J., Royce, S., Salim, M., Schaaf, H. S., Seung, K. J., Shah, L., Shean, K., Shim, T. S., Shin, S. S., Shiraishi, Y., Sifuentes-Osornio, J., Sotgiu, G., Strand, M. J., Sung, S. W., Tabarsi, P., Tupasi, T. E., Vargas, M. H., Altena, R. van, Walt, M. van der, Werf, T. S. van der, Viiklepp, P., Westenhouse, J., Yew, W. W. and Yim, J. J. (2014). Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clin Infect Dis 59, 1364–1374, http://doi.org/10.1093/cid/ciu619.
Bernard, C., Brossier, F., Fréchet-Jachym, M., Morand, P. C., Coignard, S., Aslangul, E., Aubry, A., Jarlier, V., Sougakoff, W. and Veziris, N. (2014). Concomitant Multidrug-resistant Pulmonary Tuberculosis and Susceptible Tuberculous Meningitis. Emerging Infectious Diseases 20, 506–507, http://doi.org/10.3201/eid2003.131205.
Brossier, F., Sola, C., Millot, G., Jarlier, V., Veziris, N. and Sougakoff, W. (2014). Comparison of a Semiautomated Commercial Repetitive-Sequence-Based PCR Method with Spoligotyping, 24-Locus Mycobacterial Interspersed Repetitive-Unit–Variable-Number Tandem-Repeat Typing, and Restriction Fragment Length Polymorphism-Based Analysis of IS6110 for Mycobacterium tuberculosis Typing. J Clin Microbiol 52, 4082–4086, http://doi.org/10.1128/JCM.02226-14.
Cambau, E. and Drancourt, M. (2014). Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. Clin Microbiol Infect 20, 196–201, http://doi.org/10.1111/1469-0691.12555.
de Beer, J. L., Ködmön, C., van Ingen, J., Supply, P., van Soolingen, D. and The Global Network for the Molecular Surveillance of Tuberculosis 2010 (2014). Second worldwide proficiency study on variable number of tandem repeats typing of Mycobacterium tuberculosis complex. The International Journal of Tuberculosis and Lung Disease 18, 594–600, http://doi.org/10.5588/ijtld.13.0531.
De Beer, J. L., Kodmon, C., van der Werf, M. J., van Ingen, J., van Soolingen, D. and ECDC MDR-TB Molecular Surveillance Project Participants (2014). Molecular surveillance of multi- and extensively drug-resistant tuberculosis transmission in the European Union from 2003 to 2011. Euro Surveill 19.
de Masson, A., Maillart, E., Veziris, N., Meyssonnier, V., Papeix, C. and Caumes, E. (2014). Cavitary pulmonary disease in a patient treated with natalizumab. La Presse Médicale 43, 1009–1012, http://doi.org/10.1016/j.lpm.2013.12.012.
Delafont, V., Mougaris, F., Cambau, E., Joyeux, michel, Bouchon, D., Hechard, Y. and Moulin, L. (2014). First evidence of amoebae – mycobacteria association in drinking water network. Environ Sci Technol, http://doi.org/10.1021/es5036255.
Fangous, M.-S., Mougari, F., Gouriou, S., Calvez, E., Raskine, L., Cambau, E., Payan, C. and Héry-Arnaud, G. (2014). Classification Algorithm for Subspecies Identification within the Mycobacterium abscessus Species, Based on Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. J Clin Microbiol 52, 3362–3369, http://doi.org/10.1128/JCM.00788-14.
Godreuil, S., Leban, N., Padilla, A., Hamel, R., Luplertlop, N., Chauffour, A., Vittecoq, M., Hoh, F., Thomas, F., Sougakoff, W., Lionne, C., Yssel, H. and Missé, D. (2014). Aedesin: Structure and Antimicrobial Activity against Multidrug Resistant Bacterial Strains Ed. Shih, C. PLoS ONE 9, e105441, http://doi.org/10.1371/journal.pone.0105441.
Lerat, I., Cambau, E., Bettoni, R. R. dit, Gaillard, J.-L., Jarlier, V., Truffot, C. and Veziris, N. (2014). In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus. J Infect Dis 209, 905–912, http://doi.org/10.1093/infdis/jit614.
Macheras, E., Konjek, J., Roux, A.-L., Thiberge, J.-M., Bastian, S., Leão, S. C., Palaci, M., Sivadon-Tardy, V., Gutierrez, C., Richter, E., Rüsch-Gerdes, S., Pfyffer, G. E., Bodmer, T., Jarlier, V., Cambau, E., Brisse, S., Caro, V., Rastogi, N., Gaillard, J.-L. and Heym, B. (2014). Multilocus sequence typing scheme for the Mycobacterium abscessus complex. Research in Microbiology, http://doi.org/10.1016/j.resmic.2013.12.003.
Meyssonnier, V., Bui, T. V., Veziris, N., Jarlier, V. and Robert, J. (2014). Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis. BMC Infectious Diseases 14, 18, http://doi.org/10.1186/1471-2334-14-18.
Mordant, P., Henry, B., Morel, S., Robert, J., Veziris, N., Le Dû, D., Frechet-Jachym, M., Similowski, T., Caumes, é., Riquet, M. and Le Pimpec-Barthes, F. (2014). Chirurgie et tuberculose multi/ultrarésistante : une revue de la littérature réhabilite une intervention adjuvante à l’antibiothérapie chez des patients sélectionnés. Revue des Maladies Respiratoires 31, 511–524, http://doi.org/10.1016/j.rmr.2014.01.014.
Mougari, F., Raskine, L., Ferroni, A., Marcon, E., Sermet-Gaudelus, I., Veziris, N., Heym, B., Gaillard, J.-L., Nassif, X. and Cambau, E. (2014). Clonal Relationship and Differentiation among Mycobacterium abscessus Isolates as Determined Using the Semiautomated Repetitive Extragenic Palindromic Sequence PCR-Based DiversiLab System. J Clin Microbiol 52, 1969–1977, http://doi.org/10.1128/JCM.03600-13.
Renvoise, A. and Bernard, C. (2014). Traitement des infections à Mycobacterium avium complex. J Antiinf 16, 199–206, http://doi.org/10.1016/j.antinf.2014.10.003.
Renvoise, A., Pang, S., Bernard, C., Brossier, F., Veziris, N., Capton, E., Jarlier, V. and Sougakoff, W. (2014). First Whole-Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium bovis BCG. Genome Announcements 2, e00611-14-e00611-14, http://doi.org/10.1128/genomeA.00611-14.
Renvoise, A., Bernard, C., Veziris, N., Galati, E., Jarlier, V. and Robert, J. (2014). Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare. Journal of Clinical Microbiology 52, 4439–4440, http://doi.org/10.1128/JCM.02127-14.
Ycart, B. and Veziris, N. (2014). Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. PLoS ONE 9, e101434, http://doi.org/10.1371/journal.pone.0101434.

Publications du CNR en 2015

Amarsy-Guerle, R., Mougari, F., Jacquier, H., Oliary, J., Benmansour, H., Riahi, J., Berçot, B., Raskine, L. and Cambau, E. (2015). High medical impact of implementing the new polymeric bead-based BacT/ALERT® FAPlus and FNPlus blood culture bottles in standard care. European Journal of Clinical Microbiology & Infectious Diseases 34, 1031–1037, http://doi.org/10.1007/s10096-015-2319-8.
Bernard, C., Veziris, N., Brossier, F., Sougakoff, W., Jarlier, V., Robert, J. and Aubry, A. (2015). Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 59, 1519–1524, http://doi.org/10.1128/AAC.04058-14.
Brossier, F., Sola, C., Bernard, C., Jarlier, V., Veziris, N. and Sougakoff, W. (2015). Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (−15C→T) Ed. Land, G. A. Journal of Clinical Microbiology 53, 3104–3104, http://doi.org/10.1128/JCM.01537-15.
Brossier, F., Sougakoff, W., Bernard, C., Petrou, M., Adeyema, K., Pham, A., Amy de la Breteque, D., Vallet, M., Jarlier, V., Sola, C. and Veziris, N. (2015). Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrobial Agents and Chemotherapy 59, 4800–4808, http://doi.org/10.1128/AAC.00150-15.
Bui, T. V., Lévy-Bruhl, D., Che, D., Antoine, D., Jarlier, V. and Robert, J. (2015). Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011. Euro Surveill 20.
Cambau, E., Viveiros, M., Machado, D., Raskine, L., Ritter, C., Tortoli, E., Matthys, V., Hoffner, S., Richter, E., Perez Del Molino, M. L., Cirillo, D. M., van Soolingen, D. and Bottger, E. C. (2015). Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. Journal of Antimicrobial Chemotherapy 70, 686–696, http://doi.org/10.1093/jac/dku438.
Catho, G., Couraud, S., Grard, S., Bouaziz, A., Sénéchal, A., Valour, F., Perpoint, T., Braun, E., Biron, F., Ferry, T., Chidiac, C., Freymond, N., Perrot, E., Souquet, P.-J., Maury, J.-M., Tronc, F., Veziris, N., Lina, G., Dumitrescu, O. and Ader, F. (2015). Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. Clinical Microbiology and Infection 21, 472.e7-472.e10, http://doi.org/10.1016/j.cmi.2014.12.022.
Coolen, N., Morand, P., Martin, C., Hubert, D., Kanaan, R., Chapron, J., Honoré, I., Dusser, D., Audureau, E., Veziris, N. and Burgel, P.-R. (2015). Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis 14, 594–599, http://doi.org/10.1016/j.jcf.2015.02.006.
Grard, S., Catho, G., Valour, F., Bouaziz, A., Perpoint, T., Braun, E., Biron, F., Miailhes, P., Ferry, T., Chidiac, C., Souquet, P.-J., Couraud, S., Lina, G., Goutelle, S., Veziris, N., Dumitrescu, O. and Ader, F. (2015). Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? Open Forum Infectious Diseases 2, ofv175, http://doi.org/10.1093/ofid/ofv175.
Guglielmetti, L. and Robert, J. (2015). Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux. Journal des Anti-infectieux 17, 60–66, http://doi.org/10.1016/j.antinf.2014.12.003.
Guglielmetti, L., Mougari, F., Lopes, A., Raskine, L. and Cambau, E. (2015). Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists’ point of view. Future Microbiology 10, 1467–1483, http://doi.org/10.2217/fmb.15.64.
Guglielmetti, L., Dû, D. L., Jachym, M., Henry, B., Martin, D., Caumes, Eric, Veziris, Nicolas, Métivier, N., Robert, J., Andrejak, C., Bernard, C., Brossier, F., Chadelat, K., Dautzenberg, B., Jarlier, V., Raskine, L., Rivoire, B., Veziris, N., Appere, C., Assouline, P., Borie, R., Boukari, L., Caseris, M., Caumes, E., Douadi, Y., Dumoulin, J., Duval, C., Faucher, J. F., Gallien, S., Godet, C., Grusse, J. L., Lopes, A., Meynard, J. L., Naccache, J. M., Philippe, B., Richaud, C. and Saad, H. (2015). Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clin Infect Dis 60, 188–194, http://doi.org/10.1093/cid/ciu786.
Hervé, C., Bergot, E., Veziris, N. and Blanc, F.-X. (2015). La tuberculose en 2015 : du diagnostic à la détection des formes résistantes. Revue des Maladies Respiratoires 32, 784–790, http://doi.org/10.1016/j.rmr.2015.06.008.
Isaakidis, P., Casas, E. C., Das, M., Tseretopoulou, X., Ntzani, E. E. and Ford, N. (2015). Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease 19, 969–978, http://doi.org/10.5588/ijtld.15.0123.
Jaubert, J., Mougari, F., Picot, S., Boukerrou, M., Barau, G., Ali Ahmed, S.-A., Raskine, L., Camuset, G., Michault, A., Simac, C. and Cambau, E. (2015). A case of postoperative breast infection by Mycobacterium fortuitum associated with the hospital water supply. American Journal of Infection Control 43, 406–408, http://doi.org/10.1016/j.ajic.2014.12.023.
Kibleur, Y. and Veziris, N. (2015). French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients. Chemotherapy 60, 174–179, http://doi.org/10.1159/000371869.
Reibel, F., Cambau, E. and Aubry, A. (2015). Histoire et actualité du traitement de la lèpre. Journal des Anti-Infectieux 17, 91–98, http://doi.org/10.1016/j.antinf.2015.01.004.
Reibel, F., Cambau, E. and Aubry, A. (2015). Update on the epidemiology, diagnosis, and treatment of leprosy. Médecine et Maladies Infectieuses 45, 383–393, http://doi.org/10.1016/j.medmal.2015.09.002.
Reibel, F., Chauffour, A., Brossier, F., Jarlier, V., Cambau, E. and Aubry, A. (2015). New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories Ed. Johnson, C. PLOS Neglected Tropical Diseases 9, e0004141, http://doi.org/10.1371/journal.pntd.0004141.
Renvoisé, A., Brossier, F., Galati, E., Veziris, N., Sougakoff, W., Aubry, A., Robert, J., Cambau, E., Jarlier, V. and Bernard, C. (2015). Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy 59, 7153–7155, http://doi.org/10.1128/AAC.01027-15.
Robert, J. and CNR-MyRMA (2015). Résistance aux antituberculeux en France en 2013. Bulletin Epidémiologique Hebdomadaire 9–10, 172–174, URL: http://www.invs.sante.fr/beh/2015/9-10/pdf/2015_9-10_4.pdf.
Roux, A.-L., Catherinot, E., Soismier, N., Heym, B., Bellis, G., Lemonnier, L., Chiron, R., Fauroux, B., Le Bourgeois, M., Munck, A., Pin, I., Sermet, I., Gutierrez, C., Veziris, N., Jarlier, V., Cambau, E., Herrmann, J.-L., Guillemot, D. and Gaillard, J.-L. (2015). Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. Journal of Cystic Fibrosis 14, 63–69, http://doi.org/10.1016/j.jcf.2014.07.004.